Home › Funds › RA CAPITAL MANAGEMENT, L.P. › CLYM
RA CAPITAL MANAGEMENT, L.P. position in CLYM
CLIMB BIO INC · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 11,300,939 shares of CLYM (CLIMB BIO INC) in its Q2 2026 13F filing — a position valued at US$147.4M, representing 1.28% of its reported portfolio and ranking #24 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed CLYM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s CLYM position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in CLYM in Q3 2023 at 13,150,849 shares (US$34.6M). The position peaked in Q2 2024 at 31,419,267 shares, worth US$223.4M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 11,300,939 shares valued at US$147.4M. Notable position changes include a 139% increase in Q2 2024 (shares fell 28% over the following quarter), a 64% trim in Q4 2025 (shares rose 71% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 13.15M | $34.59M | New |
| Q4 2023 | 13.15M | $35.51M | Hold |
| Q1 2024 | 13.15M | $36.03M | Hold |
| Q2 2024 | 31.42M | $223.39M | Add |
| Q3 2024 | 31.42M | $159.92M | Hold |
| Q4 2024 | 31.42M | $56.55M | Hold |
| Q1 2025 | 31.42M | $38.33M | Hold |
| Q2 2025 | 31.42M | $38.96M | Hold |
| Q3 2025 | 31.42M | $63.15M | Hold |
| Q4 2025 | 11.29M | $77.71M | Reduce |
| Q1 2026 | 11.30M | $77.41M | Hold |
| Q2 2026 | 11.30M | $147.36M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLYM and 13F data
CLYM (CLIMB BIO INC) is a Health Care company. 75 other funds we track also report a position in CLYM — the largest reported positions include BRAIDWELL LP (US$36.5M), Cormorant Asset Management, LP (US$27.5M), Redmile Group, LLC (US$16.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLYM
- BRAIDWELL LP 2.80M sh · $36.48M · Q2 2026
- Cormorant Asset Management, LP 2.11M sh · $27.46M · Q2 2026
- Redmile Group, LLC 1.23M sh · $15.99M · Q2 2026
- GREAT POINT PARTNERS LLC 1.00M sh · $13.04M · Q2 2026
- Affinity Asset Advisors, LLC 972.00K sh · $12.67M · Q2 2026
- ADAR1 Capital Management, LLC 822.65K sh · $10.73M · Q2 2026
- STEMPOINT CAPITAL LP 742.75K sh · $9.69M · Q2 2026
- Parkman Healthcare Partners LLC 563.48K sh · $7.35M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 521.08K sh · $6.79M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 483.75K sh · $6.31M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 360.65K sh · $4.70M · Q2 2026
- Ally Bridge Group (NY) LLC 249.17K sh · $3.25M · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held CLYM?
RA CAPITAL MANAGEMENT, L.P. has disclosed CLYM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in CLYM?
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 11.30M shares of CLYM (CLIMB BIO INC), valued at $147.36M, representing 1.28% of its reported portfolio and ranking #24.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling CLYM?
In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in CLYM. The position peaked in Q2 2024 at 31.42M shares.
Which other funds hold CLYM?
Other major institutional holders of CLYM include BRAIDWELL LP, Cormorant Asset Management, LP, Redmile Group, LLC, among 75 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.